BioCryst Pharmaceuticals (BCRX) News Today $7.30 +0.09 (+1.25%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Increased by Counterweight Ventures LLCCounterweight Ventures LLC grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 591.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,384 shares of the biotechnologNovember 19 at 9:48 AM | marketbeat.comBioCryst launches Orladeyo in irelandNovember 18 at 11:45 PM | markets.businessinsider.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Drop in Short InterestBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 20,830,000 shares, a drop of 7.5% from the October 15th total of 22,530,000 shares. Based on an average daily volume of 1,950,000 shares, the days-to-cover ratio is currently 10.7 days.November 18 at 7:18 AM | marketbeat.comBioCryst Launches ORLADEYO® (berotralstat) in IrelandNovember 18 at 2:00 AM | globenewswire.comBioCryst (BCRX) Receives a Buy from Bank of America SecuritiesNovember 14, 2024 | markets.businessinsider.comGSA Capital Partners LLP Sells 78,250 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)GSA Capital Partners LLP lowered its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 21.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 285,588 shares of the biotechnology company's stNovember 12, 2024 | marketbeat.comBrokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $14.67November 12, 2024 | americanbankingnews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by BrokeragesShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assignNovember 9, 2024 | marketbeat.comVanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceuticals IncNovember 7, 2024 | gurufocus.comWhat is HC Wainwright's Forecast for BCRX Q4 Earnings?BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at HC Wainwright lifted their Q4 2024 earnings estimates for BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnoNovember 7, 2024 | marketbeat.comDrugmaker eyes billion-dollar pillNovember 7, 2024 | bizjournals.comEvercore ISI Reaffirms Their Buy Rating on BioCryst (BCRX)November 7, 2024 | markets.businessinsider.comBioCryst to Present at Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Meets EstimatesBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The firm's revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.19) earnings per share.November 5, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comBioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 | finance.yahoo.comBarclays Keeps Their Hold Rating on BioCryst (BCRX)November 5, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday.November 5, 2024 | marketbeat.comBarclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) StockBarclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 5, 2024 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...November 5, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 5, 2024 | markets.businessinsider.comBioCryst: Strong Growth Potential and Strategic Positioning Underpin Buy RecommendationNovember 5, 2024 | markets.businessinsider.comBioCryst Announces Strong Q3 2024 Revenue GrowthNovember 4, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | msn.comBioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - Time to Sell?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?November 4, 2024 | marketbeat.comBioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Revenue Hits $117. ...November 4, 2024 | gurufocus.comBioCryst Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Rice Hall James & Associates LLCRice Hall James & Associates LLC grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,163,743 shares of the biotechnology company's stock afterNovember 1, 2024 | marketbeat.comSemanteon Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Semanteon Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 149,576 shares of the biotechnology company's stock, valued at approximately $1October 28, 2024 | marketbeat.comBioCryst Pharmaceuticals (BCRX) to Release Earnings on MondayBioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing earnings before the market opens on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637774)October 28, 2024 | marketbeat.comBioCryst presents evidence on high adherence, persistence rates with ORLADEYOOctober 26, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)October 24, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.7% - Here's What HappenedBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 4.7% - Here's What HappenedOctober 22, 2024 | marketbeat.comBioCryst to Report Third Quarter 2024 Financial Results on November 4October 21, 2024 | globenewswire.comBioCryst Pharma Reports New Real-World Data On Use Of Orladeyo In HAE PatientsOctober 15, 2024 | markets.businessinsider.comBioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)October 14, 2024 | globenewswire.comInspire Investing LLC Raises Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Inspire Investing LLC boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 174.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 158,008 shares of the bOctober 14, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires 113,152 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)The Manufacturers Life Insurance Company lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 113.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 212,581 shares of the biotechnology company's stock after acquiOctober 12, 2024 | marketbeat.comIs BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?October 11, 2024 | msn.comSG Americas Securities LLC Makes New $1.21 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)SG Americas Securities LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 158,921 shares of the biotechnoloOctober 10, 2024 | marketbeat.com3 Small-Cap Biotech Stocks to Buy for Major UpsideOctober 9, 2024 | stocknews.comBioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2October 9, 2024 | msn.comMillennium Management LLC Sells 279,808 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Millennium Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 13.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,751,561 shares of thOctober 8, 2024 | marketbeat.comBioCryst Pharma (NASDAQ:BCRX) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by AQR Capital Management LLCAQR Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 18.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 543,241 shares of the biotechOctober 7, 2024 | marketbeat.comBioCryst Pharma (NASDAQ:BCRX) Stock, Insider Trading ActivityOctober 7, 2024 | benzinga.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2024 | globenewswire.comBioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeOctober 2, 2024 | globenewswire.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.910.46▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼65▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TSHA News Today ADAP News Today VXRT News Today ALGS News Today PASG News Today KRYS News Today HALO News Today IONS News Today ALKS News Today FOLD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
